Prostate cancer is the most common non-skin cancer in American men. The current methods of screening for prostate cancer, which include digital rectal examinations (DREs) and serum levels of prostate specific antigen (PSA), do not detect many prostate tumors including some which are high grade and aggressive. In an effort to find better biomarkers for prostate cancer detect and prognosis. The San Antonio Center for Biomarkers of Risk of prostate cancer and genitourinary cancers (SABOR) was established in 2001. SABOR has gathered a population-based, minority-rich, cohort with extensive clinical data and biospecimens while tracking cancer-related outcomes. This cohort has been utilized for the discovery and validation of numerous new biomarkers for prostate cancer. Furthermore, specimens have been gathered for studies of bladder and kidney cancers that have been utilized by EDRN collaborators in biomarker discovery. In addition to these efforts, substantial progress has been made in the development and enhancement of the EDRN-PCPT Prostate Cancer Risk Calculator. The Risk Calculator uses numerous variables and biomarkers in addition to PSA and DRE to predict a man's risk of prostate cancer and, if detected, the chance of high-grade disease. In this current proposal, 3 specific aims are proposed: 1) We will conduct validation studies on promising serum-based biomarkers of prostate cancer;2) We will conduct validation studies of genomic markers of prostate cancer prognosis;3) We will employ results from our validation studies as well as EDRN-wide and other well-conducted validation studies to expand the applicability of the Prostate Cancer Risk Calculator, leading to individualized patient risk assessment. In support of these validation studies, the SABOR cohort will continue to be followed and additional biologies will be gathered on prostate cancer patients with long-term outcome data. In addition, the SABOR scientific personnel will continue to conduct EDRN Network validation studies, serve in leadership positions within the Network, and assist the EDRN with the design, conduct, and analysis of early detection validation studies that will alter the standard of care practice in the United States.

National Institute of Health (NIH)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Kagan, Jacob
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center
Schools of Medicine
San Antonio
United States
Zip Code
Blackburn, August; Wilson, Desiree; Gelfond, Jonathan et al. (2014) Validation of copy number variants associated with prostate cancer risk and prognosis. Urol Oncol 32:44.e15-20
Chan, Alison; Prassas, Ioannis; Dimitromanolakis, Apostolos et al. (2014) Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res 20:5787-95
Ankerst, Donna P; Boeck, Andreas; Freedland, Stephen J et al. (2014) Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol 32:185-91
Vickers, Andrew J; Sjoberg, Daniel D; Ulmert, David et al. (2014) Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 12:26
Osmulski, Pawel; Mahalingam, Devalingam; Gaczynska, Maria E et al. (2014) Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer. Prostate 74:1297-307
Thompson Jr, Ian M; Leach, Robin J; Ankerst, Donna P (2014) Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. JAMA 312:995-6
Thompson Jr, Ian M; Cabang, April B; Wargovich, Michael J (2014) Future directions in the prevention of prostate cancer. Nat Rev Clin Oncol 11:49-60
Ankerst, Donna P; Hoefler, Josef; Bock, Sebastian et al. (2014) Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology 83:1362-7
Liang, Yuanyuan; Ketchum, Norma S; Goodman, Phyllis J et al. (2014) Is there a role for body mass index in the assessment of prostate cancer risk on biopsy? J Urol 192:1094-9
Esserman, Laura J; Thompson, Ian M; Reid, Brian et al. (2014) Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 15:e234-42

Showing the most recent 10 out of 92 publications